文献速递妇科

COVID-19大流行期间妇科癌症手术的结局:一项国际多中心前瞻性CovidSurg-妇科肿瘤癌症研究

Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study.
PubMed 文献 · Am J Obstet Gynecol · 2022-06-30

这项国际多中心前瞻性队列研究纳入52个国家227个中心的3973例计划行非姑息性手术的妇科癌症患者,发现20.7%的患者诊疗方案被调整,11.2%手术延迟超过8周,延迟与疾病进展和死亡复合不良结局相关,仅0.6%手术患者围手术期感染SARS-CoV-2但感染后结局更差。

要点

  • 20.7%(823/3973)的妇科癌症患者诊疗标准被调整,11.2%(424/3784)手术延迟超过8周。
  • 延迟超过8周者复合不良结局(疾病进展和死亡)为22.4%(95/424),高于8周内手术者的17.9%(601/3360),P=.024。
  • 围手术期SARS-CoV-2感染仅0.6%(22/3778),但感染患者术后住院更长、预设手术并发症和死亡率更高。

核心结论

  • 全球约五分之一的妇科癌症手术患者在COVID-19大流行期间经历了诊疗方案调整。
  • 手术延迟或取消的患者观察到显著的不良结局,亟需协调的缓解策略。

研究设计与样本

  • 国际多中心前瞻性队列研究,纳入52个国家227个中心连续招募的 initially 计划行非姑息性手术的妇科癌症患者。
  • 自各参与中心首次COVID-19相关入院日期起招募3个月,随访期为多学科肿瘤委员会决定手术起3个月。
  • 共纳入3973例患者(3784例接受手术,189例未手术)。
  • 主要结局为疫情相关诊疗改变的发生率;次要结局包括30天围手术期死亡和并发症,以及不可切除疾病或疾病进展、急诊手术和死亡的复合结局。

主要发现

  • 20.7%(823/3973)的患者诊疗标准被调整。
  • 11.2%(424/3784)的患者手术显著延迟(>8周),卵巢癌患者尤为突出(213/1355;15.7%;P<.0001)。
  • 延迟超过8周者复合不良结局(疾病进展和死亡)为22.4%(95/424),8周内手术者为17.9%(601/3360),P=.024。
  • 13例中1例(189/2430;7.9%)未接受计划手术,其中5/189(2.7%)死亡,34/189(18%)在多学科团队决定手术后3个月内出现疾病进展或死亡。
  • 3778例手术患者中仅22例(0.6%)围手术期感染SARS-CoV-2,感染患者术后住院中位8.5天 vs 4天(P<.0001),预设手术并发症14/22(63.6%) vs 717/3762(19.1%)(P<.0001),死亡率4/22(18.2%) vs 26/3762(0.7%)(P<.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The CovidSurg-Cancer Consortium aimed to explore the impact of COVID-19 in surgical patients and services for solid cancers at the start of the pandemic. The CovidSurg-Gynecologic Oncology Cancer subgroup was particularly concerned about the magnitude of adverse outcomes caused by the disrupted surgical gynecologic cancer care during the COVID-19 pandemic, which are currently unclear. OBJECTIVE: This study aimed to evaluate the changes in care and short-term outcomes of surgical patients with gynecologic cancers during the COVID-19 pandemic. We hypothesized that the COVID-19 pandemic had led to a delay in surgical cancer care, especially in patients who required more extensive surgery, and such delay had an impact on cancer outcomes. STUDY DESIGN: This was a multicenter, international, prospective cohort study. Consecutive patients with gynecologic cancers who were initially planned for nonpalliative surgery, were recruited from the date of first COVID-19-related admission in each participating center for 3 months. The follow-up period was 3 months from the time of the multidisciplinary tumor board decision to operate. The primary outcome of this analysis is the incidence of pandemic-related changes in care. The secondary outcomes included 30-day perioperative mortality and morbidity and a composite outcome of unresectable disease or disease progression, emergency surgery, and death. RESULTS: We included 3973 patients (3784 operated and 189 nonoperated) from 227 centers in 52 countries and 7 world regions who were initially planned to have cancer surgery. In 20.7% (823/3973) of the patients, the standard of care was adjusted. A significant delay (>8 weeks) was observed in 11.2% (424/3784) of patients, particularly in those with ovarian cancer (213/1355; 15.7%; P<.0001). This delay was associated with a composite of adverse outcomes, including disease progression and death (95/424; 22.4% vs 601/3360; 17.9%; P=.024) compared with those who had operations within 8 weeks of tumor board decisions. One in 13 (189/2430; 7.9%) did not receive their planned operations, in whom 1 in 20 (5/189; 2.7%) died and 1 in 5 (34/189; 18%) experienced disease progression or death within 3 months of multidisciplinary team board decision for surgery. Only 22 of the 3778 surgical patients (0.6%) acquired perioperative SARS-CoV-2 infections; they had a longer postoperative stay (median 8.5 vs 4 days; P<.0001), higher predefined surgical morbidity (14/22; 63.6% vs 717/3762; 19.1%; P<.0001) and mortality (4/22; 18.2% vs 26/3762; 0.7%; P<.0001) rates than the uninfected cohort. CONCLUSION: One in 5 surgical patients with gynecologic cancer worldwide experienced management modifications during the COVID-19 pandemic. Significant adverse outcomes were observed in those with delayed or cancelled operations, and coordinated mitigating strategies are urgently needed.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Fotopoulou C, Khan T, Bracinik J, et al. Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study. Am J Obstet Gynecol. 2022. PMID: 35779589. doi:10.1016/j.ajog.2022.06.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。